Highlights Pulmatrix, Inc.

Equities

PULM

US74584P3010

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-08 EDT			5-day change	1st Jan Change
1.89 ^USD	-0.01%		-0.01%	+1.61%

03-28	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-13	Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	01-08	DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	01-08	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	11-09	MT
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-23	CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M	23-08-10	MT
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	23-07-11	CI
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $1.5M	23-05-12	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma	23-02-06	CI
Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine, for Acute Migraine	23-01-04	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M	22-11-10	MT
Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine	22-09-26	CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.33M	22-08-08	MT
Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine	22-07-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pulmatrix, Inc.

Equities

PULM

US74584P3010

Highlights

Filters